Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rosa Segarra"'
Autor:
Jutta Beier, Anne-Marie Kirsten, Robert Mróz, Rosa Segarra, Ferran Chuecos, Cynthia Caracta, Esther Garcia Gil
Publikováno v:
COPD, Vol 10, Iss 4, Pp 511-522 (2013)
AbstractBackground: This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide versus placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). M
Externí odkaz:
https://doaj.org/article/dc395413bf4942b1a3f2071d24e9137b
Autor:
Surinder S. Birring, Antonio Zapata, Beatriz Seoane, Alyn H. Morice, Massimo Notari, Rosa Segarra, Jadwiga A. Wedzicha, Lorcan McGarvey, Diana Jarreta, Jaclyn A. Smith
Publikováno v:
Smith, J A, McGarvey, L, Morice, A H, Birring, S S, Wedzicha, J A, Notari, M, Zapata, A, Segarra, R, Seoane, B & Jarreta, D 2019, ' The effect of aclidinium on symptoms including cough in chronic obstructive pulmonary disease : A phase 4, double-blind, placebo-controlled, parallel-group study ', American Journal of Respiratory and Critical Care Medicine, vol. 200, no. 5, pp. 642-645 . https://doi.org/10.1164/rccm.201901-0048LE
American Journal of Respiratory and Critical Care Medicine
American Journal of Respiratory and Critical Care Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::466719ab78cb0ebcf35c0c021e1bfa79
https://www.research.manchester.ac.uk/portal/en/publications/the-effect-of-aclidinium-on-symptoms-including-cough-in-chronic-obstructive-pulmonary-disease(b7158396-57b6-476f-a61e-a19419d8e0ff).html
https://www.research.manchester.ac.uk/portal/en/publications/the-effect-of-aclidinium-on-symptoms-including-cough-in-chronic-obstructive-pulmonary-disease(b7158396-57b6-476f-a61e-a19419d8e0ff).html
Autor:
Gary T. Ferguson, Robert Mróz, Diana Jarreta, Rosa Segarra, Esther Garcia Gil, Edward Kerwin, Henrik Watz, Eduard Molins, Sanjay Sethi
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Sanjay Sethi,1 Edward Kerwin,2 Henrik Watz,3 Gary T Ferguson,4 Robert M Mroz,5,6 Rosa Segarra,7 Eduard Molins,7 Diana Jarreta,7 Esther Garcia Gil7 1Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA; 2Cli
Autor:
Anne-Marie Kirsten, Anne Leselbaum, Rosa Segarra, Pierluigi Paggiaro, Jutta Beier, Pawel Sliwinski, Jordi Dorca, Marcel Mallet, Claus Vogelmeier, Beatriz Seoane
Publikováno v:
European Respiratory Journal. 48:1030-1039
The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium
Autor:
Henrik Watz, Robert Mróz, Gary T. Ferguson, Sanjay Sethi, Diana Jarreta, Edward Kerwin, Eduard Molins, Rosa Segarra, Esther García-Gil
Publikováno v:
Airway pharmacology and treatment.
Background: Aclidinium bromide (AB) and tiotropium (TIO) are long-acting anti-muscarinic COPD maintenance therapies. AB has not been compared with TIO beyond 6 weeks (wks). Aim: To compare efficacy and safety of AB vs TIO at 24 wks in symptomatic pat
Autor:
Anne-Marie Kirsten, Rosa Segarra, Robert Mróz, Esther Garcia Gil, Jutta Beier, Cynthia Caracta, Ferran Chuecos
Publikováno v:
COPD
Background: This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide versus placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Methods:
Autor:
Claus Vogelmeier, G de Miquel, Sergi Pascual, Robert Mróz, Alejhandra Lei, Jutta Beier, Rosa Segarra
Publikováno v:
Pneumologie. 70
Autor:
Rosa Lamarca, Rosa Segarra, Eric D. Bateman, Paul W. Jones, Esther Garcia Gil, Cynthia Caracta, Gonzalo de Miquel, Alvar Agusti, Dave Singh
Publikováno v:
European Respiratory Journal. 40:830-836
The efficacy and safety of two doses of aclidinium bromide were evaluated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). In this 24-week, double-blind trial, patients were randomised to twice-daily aclidinium (200
Autor:
Robert Mróz, Claus F. Vogelmeier, Gonzalo de Miquel, Jutta Beier, Sergi Pascual, Alejhandra Lei, Rosa Segarra
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Background: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) twice daily (BID) is approved in Europe for the treatment of COPD. Aim: To evaluate overall and cardiovascular (CV) safety of aclidinium/formoterol FDC vs salmeterol/flut
Autor:
Esther Garcia Gil, Beatriz Seoane, Anne-Marie Kirsten, Anne Leselbaum, Jordi Dorca, Pierluigi Paggiaro, Pawel Sliwinski, Claus F. Vogelmeier, Rosa Segarra, Marcel Mallet
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Background: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) twice daily (BID) is licensed in Europe for COPD treatment. Aim: To evaluate the efficacy of aclidinium/formoterol vs salmeterol/fluticasone propionate FDC (SAL/FLU) in p